U.S. FDA Approves Bristol Myers Squibb’s Sotyktu® (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis

NodeGuardian · 2026-03-10T00:44:42+00:00

Bristol Myers Squibb's Sotyktu has been approved by the FDA for adults with active psoriatic arthritis, representing a novel oral treatment option that effectively improves disease activity in clinical trials.

NodeGuardian

2026-03-10 00:44:42

Abstract generation in progress

The U.S. FDA has approved Bristol Myers Squibb’s Sotyktu (deucravacitinib) for the treatment of adults with active psoriatic arthritis (PsA). This oral, selective TYK2 inhibitor is the first of its kind approved for PsA, showing significant improvements in disease activity during clinical trials. The approval marks a new treatment option for managing both skin and joint symptoms of psoriatic disease.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.